Glaxo Group Limited

Michael Mary Van Oort

Richard Ian Walker

Andrew Bruce Brown

Verna Lo Clark

A dry powder pharmaceutical composition comprising (i) a medicament particle fraction comprising medicament particles with an aerodynamic diameter no greater than 10 &#x3bc;m; and (ii) at least 50% of a non-respirable excipient fraction comprising low density excipient particles with an aerodynamic diameter greater than 10 &#x3bc;m and a geometric diameter greater than 30 &#x3bc;m. In additional embodiments of the invention, the pharmaceutical composition includes a respirable excipient fraction comprising excipient particles with an aerodynamic diameter no greater than 10 &#x3bc;m. In a preferred embodiment of the invention, the non-respirable excipient particles include pores adapted to receive a portion of the respirable excipient fraction and/or the medicament fraction.

Dry powder medicament formulations

A laminate assembly, comprising a base sheet having at least one blister formed therein, a pharmaceutical composition displaced in the blister, a lid sheet bonded to the base sheet to form a primary seal therebetween, thus forming a primarily sealed laminate assembly; the primary sealed laminate assembly having a secondary seal formed therein, and related manufacturing method and system of manufacture.

Growing community of inventors

Durham, NC, United States of America

Michael Mary Van Oort